Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Rigaudeau, Sophie" or (type any "bookEditor issueEditor" and editor="Rigaudeau, Sophie")

Add to list
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Arthur Bobin, Maeva Kyheng, Stephanie Guidez, Cecile Gruchet-Merouze, Valentine Richez, Alain Duhamel, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, et al.

(2022) LEUKEMIA. 36(3). p.881-884
Add to list
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner (UGent) , Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, et al.

(2021) BLOOD. 137(26). p.3616-3628
Add to list
Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial

Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Michel Attal, Fritz Offner (UGent) , Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, et al.

(2020) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 20(Supplement 1). p.S307-S308
Add to list
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

Xavier Leleu, Guillemette Fouquet, Valentine Richez, Stephanie Guidez, Alain Duhamel, Francois Machuron, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, et al.

(2019) CLINICAL CANCER RESEARCH. 25(14). p.4224-4230
Add to list
- Conference Paper
- C3
IFM2012-03

Xavier Leleu, Guillemette Fouquet, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Jv Malfuson, Pascal Bourquard, Pascal Lenain, et al.

(2016) BLOOD. 128(22).
Add to list
- Conference Paper
- C3
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

Xavier Leleu, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Thierry De Revel, Pascal Bourquard, Pascal Lenain, Murielle Roussel, et al.

(2015) BLOOD. 126(23).

Academic Bibliography

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

IFM2012-03

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

Contents

Support

Contact